MORGAN STANLEY PLC/CALL/MEDTRONIC/110/0.1/21.06.24 Stock

Warrant

DE000MB8M3W3

Market Closed - Börse Stuttgart 14:37:24 2024-05-31 EDT
0.012 EUR -.--% Intraday chart for MORGAN STANLEY PLC/CALL/MEDTRONIC/110/0.1/21.06.24
1 month-7.69%
3 months-42.86%
Date Price Change
24-05-31 0.012 -.--%
24-05-30 0.012 -.--%
24-05-29 0.012 +9.09%
24-05-28 0.011 -.--%
24-05-27 0.011 -15.38%

Delayed Quote Börse Stuttgart

Last update May 31, 2024 at 02:37 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying MEDTRONIC PLC
Issuer Morgan Stanley
WKN MB8M3W
ISINDE000MB8M3W3
Date issued 2023-07-12
Strike 110 $
Maturity 2024-06-21 (20 Days)
Parity 10 : 1
Emission price 0.15
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.179
Lowest since issue 0.001
Delta0.05x
Omega 14.71
Premium35.53x
Gearing288.5x
Moneyness 0.7397
Difference Strike 28.63 $
Difference Strike %+26.03%
Spread 0.028
Spread %70.00%
Theoretical value 0.0260
Implied Volatility 72.18 %
Total Loss Probability 96.48 %
Intrinsic value 0.000000
Present value 0.0260
Break even 110.28 €
Theta-0.02x
Vega0x
Rho0x

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
81.37 USD
Average target price
94.07 USD
Spread / Average Target
+15.61%
Consensus